Publication details.

Paper

Year:2019
Author(s):M. Pastor, J. Basas, C. Vairo, G. Gainza, M. Moreno-Sastre, X. Gomis, A. Fleischer, E. Palomino, D. Bachiller, F. Gutiérrez, J. Aguirre, A. Esquisabel, M. Igartua, E. Gainza, R. Hernandez, J. Gavaldà, J. Pedraz
Title:Safety and effectiveness of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) against P. aeruginosa: in vitro and in vivo studies following pulmonary and intramuscular administration
Journal:Nanomedicine-Nanotechnology Biology and Medicine
ISSN:1549-9634
JCR Impact Factor:5.182
Volume:18
Pages:101-111
D.O.I.:10.1016/j.nano.2019.02.014
Web:https://dx.doi.org/10.1016/j.nano.2019.02.014
Abstract:© 2019 Elsevier Inc.The usefulness of nanotechnology to increase the bioavailability of drugs and decrease their toxicity may be a tool to deal with multiresistant P. aeruginosa (Mr-Pa) respiratory infections. We describe the preparation and the in vivo efficacy and safety of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) by the pulmonary and intramuscular routes. Nanoparticles showed 1-2 mg/L minimum inhibitory concentration against eight extensively drug-resistant P. aeruginosa strains. In vivo, SCM-NLC displayed significantly lower CFU/g lung than the saline and similar to that of the free SCM, even the dose in SCM-NLC group was lower than free SCM. There was no tissue damage related to the treatments. Biodistribution assessments showed a mild systemic absorption after nebulization and a notorious absorption after IM route. Altogether, it could be concluded that SCM-NLC were effective against P. aeruginosa in vivo, not toxic and distribute efficiently to the lung and liver after pulmonary or intramuscular administrations.

Related departments

  • External Staff
  • CSIC staff non-ascribed